Uncomplicated Malaria Clinical Trial
Official title:
A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)
Plasmodium vivax can form dormant liver stages that reactivate weeks or months following an
acute infection. Recurrent infections can be associated with a febrile illness, a cumulative
risk of severe anaemia, and even mortality. In co-endemic areas the risk of recurrence after
both P. vivax and P. falciparum infections can be over 50% within 3 months. The only drug we
have to kill P. vivax hypnozoites is primaquine which is currently given as a 14 day regimen.
In Papua a retrospective study found very low effectiveness for unsupervised treatment. If
true this has profound effects on treatment policy, suggesting that greater efforts are
needed to encourage adherence to treatment.
We propose a cluster randomized, controlled, open label trial to assess the effectiveness of
unsupervised versus supervised primaquine treatment in patients with uncomplicated malaria.
Since the risk of recurrent P. vivax is high in patients with either P. vivax or P.
falciparum, both infections will be included in the study. The study will be conducted in
Mimika, in the southern part of Papua Province, Indonesia. Participants will be enrolled at
village health posts and provided with schizontocidal treatment plus primaquine radical cure
which will be either supervised or unsupervised depending on which cluster the clinic is in.
Participants will be followed up for 6 months and assessed in regular intervals for the
presence of patent and sub-patent malaria. The outcome of the study will contribute to an
improved treatment scheme for uncomplicated malaria in this area.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT00540202 -
Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children
|
Phase 4 | |
| Completed |
NCT01213433 -
Amodiaquine+Artesunate for Uncomplicated Malaria Treatment
|
Phase 4 | |
| Active, not recruiting |
NCT00406146 -
Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children
|
Phase 3 | |
| Completed |
NCT05192265 -
Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine
|
Phase 2/Phase 3 | |
| Completed |
NCT04767191 -
Malaria Therapeutic Efficacy Study (TES) Kenya
|
Phase 4 | |
| Completed |
NCT04767217 -
Malaria Therapeutic Efficacy Study, Rwanda
|
Phase 4 | |
| Completed |
NCT06036030 -
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua
|
Phase 2 | |
| Recruiting |
NCT06064591 -
Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
|
||
| Completed |
NCT06300970 -
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia
|
Phase 4 | |
| Completed |
NCT00845533 -
Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina Faso
|
Phase 4 | |
| Completed |
NCT03387631 -
Efficacy And Safety Of AL For The Treatment Of Uncomplicated Falciparum Malaria In Mainland Tanzania
|
N/A | |
| Completed |
NCT00868465 -
Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)
|
N/A | |
| Completed |
NCT00460369 -
Treatment of Uncomplicated Malaria in Benin
|
N/A | |
| Completed |
NCT00459615 -
Phase II Dose Ranging Study of Artesunate
|
Phase 2 | |
| Not yet recruiting |
NCT05911828 -
A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
|
Phase 1 |